LA JOLLA, CA, April 30, 2024 – Enlaza Therapeutics, the first covalent biologic platform company, today announced a $100 million Series A financing. The financing will be used to further...
Sorriso is a biopharmaceutical company advancing a pipeline of disease-modifying antibodies for the treatment of immune-mediated diseases, including Crohn’s disease and ulcerative colitis. The company's platform generates potent antibodies that can be delivered orally and are designed to maintain activity throughout the human intestine.
© 2024 Pappas Capital, LLC. ALL RIGHTS RESERVED.